These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 16537250)

  • 1. Urinary excretion of 11-nor-9-carboxy-Delta9- tetrahydrocannabinol: a case with an apparent long terminal half-life.
    Smith-Kielland A
    Scand J Clin Lab Invest; 2006; 66(2):169-71. PubMed ID: 16537250
    [No Abstract]   [Full Text] [Related]  

  • 2. The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans.
    Dietz L; Glaz-Sandberg A; Nguyen H; Skopp G; Mikus G; Aderjan R
    Ther Drug Monit; 2007 Jun; 29(3):368-72. PubMed ID: 17529896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of thin-layer chromatography for detection of 11-nor-9-carboxy-delta9-tetrahydrocannabinol in the urine].
    Nikonova EV; Karaeva LD
    Sud Med Ekspert; 2005; 48(5):33-5. PubMed ID: 16279498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for marijuana and cocaine abuse by immunoanalysis and gas chromatography.
    Garcia-Jimenez S; Heredia-Lezama K; Bilbao-Marcos F; Fuentes-Lara G; Monroy-Noyola A; Deciga-Campos M
    Ann N Y Acad Sci; 2008 Oct; 1139():422-5. PubMed ID: 18991889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Postmortem detection of hemp intoxication].
    Morozov IuE; Mammadov VK; Kopylov AV
    Sud Med Ekspert; 2003; 46(5):21-4. PubMed ID: 14584408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged excretion half-life of 11-nor-9-carboxy-Δ⁹-THC following cessation in a chronic, heavy marijuana user: implications for liver transplant assessment.
    Chaiffetz D; Dimartini AF; Venkataramanan R
    Psychosomatics; 2011; 52(2):190-3. PubMed ID: 21397113
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects.
    Glaz-Sandberg A; Dietz L; Nguyen H; Oberwittler H; Aderjan R; Mikus G
    Clin Pharmacol Ther; 2007 Jul; 82(1):63-9. PubMed ID: 17410118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study assessing maternal marijuana use by urine assay during pregnancy.
    Zuckerman BS; Hingson RW; Morelock S; Amaro H; Frank D; Sorenson JR; Kayne HL; Timperi R
    NIDA Res Monogr; 1985; 57():84-93. PubMed ID: 2993891
    [No Abstract]   [Full Text] [Related]  

  • 9. Determination of plasma and urine levels of Delta9-tetrahydrocannabinol and its main metabolite by liquid chromatography after solid-phase extraction.
    Mercolini L; Musenga A; Comin I; Baccini C; Conti M; Raggi MA
    J Pharm Biomed Anal; 2008 May; 47(1):156-63. PubMed ID: 18242913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous determination of amphetamine-type stimulants and cannabinoids in fingernails by gas chromatography-mass spectrometry.
    Kim JY; Cheong JC; Kim MK; Lee JI; In MK
    Arch Pharm Res; 2008 Jun; 31(6):805-13. PubMed ID: 18563365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged apparent half-life of delta 1-tetrahydrocannabinol in plasma of chronic marijuana users.
    Johansson E; Agurell S; Hollister LE; Halldin MM
    J Pharm Pharmacol; 1988 May; 40(5):374-5. PubMed ID: 2899638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High potency cannabis: the forgotten variable.
    Smith N
    Addiction; 2005 Oct; 100(10):1558-60; author reply 1560-1. PubMed ID: 16185219
    [No Abstract]   [Full Text] [Related]  

  • 13. Using sweeping micellar electrokinetic chromatography to analyze Delta9-tetrahydrocannabinol and its major metabolites.
    Su HL; Feng LI; Jen HP; Hsieh YZ
    J Chromatogr A; 2009 Apr; 1216(16):3512-7. PubMed ID: 18945437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevalence of the use of cannabis in a young population].
    Plans P; Vaqué J; Artanza MA
    Med Clin (Barc); 1986 Apr; 86(16):697-8. PubMed ID: 3016420
    [No Abstract]   [Full Text] [Related]  

  • 15. Determination of delta9-tetrahydrocannabinol in indoor air as an indicator of marijuana cigarette smoking using adsorbent sampling and in-injector thermal desorption gas chromatography-mass spectrometry.
    Chou SL; Ling YC; Yang MH; Pai CY
    Anal Chim Acta; 2007 Aug; 598(1):103-9. PubMed ID: 17693313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques.
    Jung J; Meyer MR; Maurer HH; Neusüss C; Weinmann W; Auwärter V
    J Mass Spectrom; 2009 Oct; 44(10):1423-33. PubMed ID: 19728318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Delta9-tetrahydrocannabinolic acid A in human urine and blood serum by LC-MS/MS.
    Jung J; Kempf J; Mahler H; Weinmann W
    J Mass Spectrom; 2007 Mar; 42(3):354-60. PubMed ID: 17219606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between non-acute adolescent cannabis use and cognition.
    Harvey MA; Sellman JD; Porter RJ; Frampton CM
    Drug Alcohol Rev; 2007 May; 26(3):309-19. PubMed ID: 17454021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-catalyzed oxidation of delta(9)-tetrahydrocannabinol.
    Brogan AP; Eubanks LM; Koob GF; Dickerson TJ; Janda KD
    J Am Chem Soc; 2007 Mar; 129(12):3698-702. PubMed ID: 17335216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.
    Sachse-Seeboth C; Pfeil J; Sehrt D; Meineke I; Tzvetkov M; Bruns E; Poser W; Vormfelde SV; Brockmöller J
    Clin Pharmacol Ther; 2009 Mar; 85(3):273-6. PubMed ID: 19005461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.